nach oben

Erschienen in:

01.05.2010 | Position Paper

The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES)

verfasst von: O. Bruyere, J. A. Kanis, M.-E. Ibar-Abadie, N. Alsayed, M. L. Brandi, N. Burlet, D. L. Cahall, A. Chines, J.-P. Devogelaer, W. Dere, N. Goel, N. Hughes, J.-M. Kaufman, S. Korte, B. H. Mitlak, D. Niese, R. Rizzoli, L. C. Rovati, J.-Y. Reginster

Erschienen in: Osteoporosis International | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Summary

This paper provides recommendations for fair and unbiased relationship between academic scientists and the pharmaceutical industry.

Introduction

Real or perceived problems in the relationship between academics and the industry have been the subject of much recent debate. It has been suggested that academic clinicians should sever all links with the industry—a view that is rarely challenged.

Methods

Academic experts and members of the pharmaceutical industry were invited to an expert consensus meeting to debate this topic. This meeting was organized by the Group for the Respect of Ethics and Excellence in Science. Conflict of interest, competing interest, right and duties of academic scientist, authorship, and staff and student education were discussed.

Results

Guidelines for a transparent, ethical, strong, and successful partnership between the academic scientist and the pharmaceutical industry have been provided.

Conclusions

The Group support interactions between the industry and clinicians provided that it is transparent and ethical.

Walsh K, Sandars J (2008) Competing interests and research in medical education. Postgrad Med J 84:113–114CrossRefPubMed

Haines IE, Olver IN (2008) Are self-regulation and declaration of conflict of interest still the benchmark for relationships between physicians and industry? Med J Aust 189:263–266PubMed

Shaldon S (2008) Conflict of interest in clinical guidelines should be avoided. Nephrol Dial Transplant 23:1771, author reply 1772CrossRefPubMed

Elliott KC (2008) Scientific judgment and the limits of conflict-of-interest policies. Account Res 15:1–29PubMed

Sismondo S (2008) How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Soc Sci Med 66:1909–1914CrossRefPubMed

Doucet M, Sismondo S (2008) Evaluating solutions to sponsorship bias. J Med Ethics 34:627–630CrossRefPubMed

Chabner BA (2008) Conflict of interest: in the eye of the beholder? Oncologist 13:212–213CrossRefPubMed

Camilleri M, Cortese DA (2007) Managing conflict of interest in clinical practice. Mayo Clin Proc 82:607–614CrossRefPubMed

Tungaraza T, Poole R (2007) Influence of drug company authorship and sponsorship on drug trial outcomes. Br J Psychiatry 191:82–83CrossRefPubMed

10.

Duvall DG (2006) Conflict of interest or ideological divide: the need for ongoing collaboration between physicians and industry. Curr Med Res Opin 22:1807–1812CrossRefPubMed

11.

Weinfurt KP, Friedman JY, Dinan MA, Allsbrook JS, Hall MA, Dhillon JK, Sugarman J (2006) Disclosing conflicts of interest in clinical research: views of institutional review boards, conflict of interest committees, and investigators. J Law Med Ethics 34(581–591):481

12.

Bekelman JE, Li Y, Gross CP (2003) Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289:454–465CrossRefPubMed

13.

Shaywitz D, Stossel T (2009) It’s time to fight the “PharmaScolds”. In Wall Street Journal

14.

Collier J (2009) Doctors, patients, and the pharmaceutical industry. BMJ 338:b443CrossRefPubMed

15.

Royal-College-of-Physicians (2009) Innovating for health: patient, physicians, the pharmaceutical industry and the NHS. Report of a Working Party, London

16.

Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, Nissen SE, Osborn JE, Scully JH Jr, Thomson GE, Wofsy D (2009) Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA 301:1367–1372CrossRefPubMed

17.

Christensen JA, Orlowski JP (2005) Bounty-hunting and finder’s fees. IRB 27:16–19CrossRefPubMed

18.

Moses H 3rd, Dorsey ER, Matheson DH, Thier SO (2005) Financial anatomy of biomedical research. JAMA 294:1333–1342CrossRefPubMed

19.

Olesen J, Lekander I, Andlin-Sobocki P, Jonsson B (2007) Funding of headache research in Europe. Cephalalgia 27:995–999CrossRefPubMed

20.

Philipson L (2005) Medical research activities, funding, and creativity in Europe: comparison with research in the United States. JAMA 294:1394–1398CrossRefPubMed

21.

Demotes-Mainard J, Canet E, Segard L (2006) Public–private partnership models in France and in Europe. Therapie 61(325–334):313–323CrossRef

22.

Moses H 3rd, Braunwald E, Martin JB, Thier SO (2002) Collaborating with industry—choices for the academic medical center. N Engl J Med 347:1371–1375CrossRefPubMed

23.

Bero LA, Glantz S, Hong MK (2005) The limits of competing interest disclosures. Tob Control 14:118–126PubMed

24.

Sismondo S (2008) Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials 29:109–113CrossRefPubMed

25.

Niebyl JR (2008) The pharmaceutical industry: friend or foe? Am J Obstet Gynecol 198:435–439CrossRefPubMed

26.

Haas J (2008) Commentary: epidemiology and the pharmaceutical industry: an inside perspective. Int J Epidemiol 37:53–55, discussion 65-58CrossRefPubMed

27.

Boyd EA, Bero LA (2007) Defining financial conflicts and managing research relationships: an analysis of university conflict of interest committee decisions. Sci Eng Ethics 13:415–435CrossRefPubMed

28.

Sismondo S (2007) Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Med 4:e286CrossRefPubMed

29.

Reginster JY (2007) The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum 56:2105–2110CrossRefPubMed

30.

Pharmaceutical Research and Manufacturers of America (PhRMA) (2008) Code on interactions with healthcare professionals

31.

Wager E, Field EA, Grossman L (2003) Good publication practice for pharmaceutical companies. Curr Med Res Opin 19:149–154CrossRefPubMed

32.

Schulman KA, Seils DM, Timbie JW, Sugarman J, Dame LA, Weinfurt KP, Mark DB, Califf RM (2002) A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med 347:1335–1341CrossRefPubMed

33.

Campbell P (2001) Declaration of financial interests. Nature 412:751CrossRefPubMed

34.

Wager E (2004) The need for trial identifiers. Curr Med Res Opin 20:203–206CrossRefPubMed

35.

Hirsch L (2008) Trial registration and results disclosure: impact of US legislation on sponsors, investigators, and medical journal editors. Curr Med Res Opin 24:1683–1689CrossRefPubMed

36.

Goldhahn J, Mitlak B, Aspenberg P, Kanis JA, Rizzoli R, Reginster JY (2008) Critical issues in translational and clinical research for the study of new technologies to enhance bone repair. J Bone Jt Surg Am 90(Suppl 1):43–47CrossRef

37.

Compston J, Reid DM, Boisdron J, Brandi ML, Burlet N, Cahall D, Delmas PD, Dere W, Devogelaer JP, Fitzpatrick LA, Flamion B, Goel N, Korte S, Laslop A, Mitlak B, Ormarsdottir S, Ringe J, Rizzoli R, Tsouderos Y, Van Staa T, Reginster JY (2008) Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos Int 19:1247–1250CrossRefPubMed

38.

Lekkerkerker F, Kanis JA, Alsayed N, Bouvenot G, Burlet N, Cahall D, Chines A, Delmas P, Dreiser RL, Ethgen D, Hughes N, Kaufman JM, Korte S, Kreutz G, Laslop A, Mitlak B, Rabenda V, Rizzoli R, Santora A, Schimmer R, Tsouderos Y, Viethel P, Reginster JY (2007) Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 18:1311–1317CrossRefPubMed

39.

Reginster JY, Abadie E, Delmas P, Rizzoli R, Dere W, der Auwera P, Avouac B, Brandi ML, Daifotis A, Diez-Perez A, Calvo G, Johnell O, Kaufman JM, Kreutz G, Laslop A, Lekkerkerker F, Mitlak B, Nilsson P, Orloff J, Smillie M, Taylor A, Tsouderos Y, Ethgen D, Flamion B (2006) Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. Osteoporos Int 17:1–7CrossRefPubMed

40.

Abadie E, Ethgen D, Avouac B, Bouvenot G, Branco J, Bruyere O, Calvo G, Devogelaer JP, Dreiser RL, Herrero-Beaumont G, Kahan A, Kreutz G, Laslop A, Lemmel EM, Nuki G, Van De Putte L, Vanhaelst L, Reginster JY (2004) Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis Cartilage 12:263–268CrossRefPubMed

41.

Holgate ST, Bousquet J, Chung KF, Bisgaard H, Pauwels R, Fabbri L, Rabe K, Doherty M, Snell NJ, Cuss F, D’Amato M, Reginster JY (2004) Summary of recommendations for the design of clinical trials and the registration of drugs used in the treatment of asthma. Respir Med 98:479–487CrossRefPubMed

42.

Delmas PD, Calvo G, Boers M, Abadie E, Avouac B, Kahan A, Kaufman JM, Laslop A, Lekkerkerker JF, Nilsson P, Van Zwieten-Boot B, Kreutz G, Reginster JY (2002) The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis. Osteoporos Int 13:1–5CrossRefPubMed

43.

Vignon E, Garnero P, Delmas P, Avouac B, Bettica P, Boers M, Ehrich E, MacKillop N, Rovati L, Serni U, Spector T, Reginster JY (2001) Recommendations for the registration of drugs used in the treatment of osteoarthritis: an update on biochemical markers. Osteoarthritis Cartilage 9:289–293CrossRefPubMed

44.

Group for the Respect of Ethics and Excellence in Science (GREES) (1998) Recommendations for the registration of drugs used in the treatment of rheumatoid arthritis: rheumatoid arthritis section. Br J Rheumatol 37:211–215CrossRef

45.

Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, Fujiwara S, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16:155–162CrossRefPubMed

46.

Horrobin DF (1999) Beyond conflict of interest. Non-financial conflicts of interest are more serious than financial conflicts. BMJ 318:466PubMed

47.

The PLoS Medicine Editors (2008) Making sense of non-financial competing interests. PLoS Med 5:e199CrossRef

48.

Bero L (2008) “Experimental” institutional models for corporate funding of academic research: unknown effects on the research enterprise. J Clin Epidemiol 61:629–633CrossRefPubMed

49.

de Haas ER, de Vijlder HC, van Reesema WS, van Everdingen JJ, Neumann HA (2007) Quality of clinical practice guidelines in dermatological oncology. J Eur Acad Dermatol Venereol 21:1193–1198PubMed

50.

Reed DA, Cook DA, Beckman TJ, Levine RB, Kern DE, Wright SM (2007) Association between funding and quality of published medical education research. JAMA 298:1002–1009CrossRefPubMed

51.

Lexchin J, Bero LA, Djulbegovic B, Clark O (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326:1167–1170CrossRefPubMed

52.

Angell M, Kassirer JP (1996) Editorials and conflicts of interest. N Engl J Med 335:1055–1056CrossRefPubMed

53.

Drazen JM, Curfman GD (2002) Financial associations of authors. N Engl J Med 346:1901–1902CrossRefPubMed

54.

Ancker JS, Flanagin A (2007) A comparison of conflict of interest policies at peer-reviewed journals in different scientific disciplines. Sci Eng Ethics 13:147–157CrossRefPubMed

55.

Chaudhry S, Schroter S, Smith R, Morris J (2002) Does declaration of competing interests affect readers’ perceptions? A randomised trial. BMJ 325:1391–1392CrossRefPubMed

56.

Healy D, Cattell D (2003) Interface between authorship, industry and science in the domain of therapeutics. Br J Psychiatry 183:22–27CrossRefPubMed

57.

McLennan M, Leong FC, Steele A, Harris J (2008) The influence of industry sponsorship on the acceptance of abstracts and their publication. Am J Obstet Gynecol 198(579):e571–e574

58.

Davidoff F, DeAngelis CD, Drazen JM, Hoey J, Hojgaard L, Horton R, Kotzin S, Nicholls MG, Nylenna M, Overbeke AJ, Sox HC, Van Der Weyden MB, Wilkes MS (2001) Sponsorship, authorship, and accountability. Lancet 358:854–856CrossRefPubMed

59.

Bodenheimer T (2000) Uneasy alliance—clinical investigators and the pharmaceutical industry. N Engl J Med 342:1539–1544CrossRefPubMed

60.

International Committee of Medical Journal Editors (1997) Uniform requirements for manuscripts submitted to biomedical journals. JAMA 277:927–934CrossRef

61.

Graf C, Battisti WP, Bridges D, Bruce-Winkler V, Conaty JM, Ellison JM, Field EA, Gurr JA, Marx ME, Patel M, Sanes-Miller C, Yarker YE (2009) Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ 339:b4330CrossRefPubMed

62.

Jacobs A, Wager E (2005) European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications. Curr Med Res Opin 21:317–322CrossRefPubMed

63.

Norris R, Bowman A, Fagan JM, Gallagher ER, Geraci AB, Gertel A, Hirsch L, Ross PD, Stossel TP, Veitch K, Woods D (2007) International Society for Medical Publication Professionals (ISMPP) position statement: the role of the professional medical writer. Curr Med Res Opin 23:1837–1840CrossRefPubMed

64.

Moher D, Schulz KF, Altman D (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 285:1987–1991CrossRefPubMed

Titel: The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES)
verfasst von: O. Bruyere
J. A. Kanis
M.-E. Ibar-Abadie
N. Alsayed
M. L. Brandi
N. Burlet
D. L. Cahall
A. Chines
J.-P. Devogelaer
W. Dere
N. Goel
N. Hughes
J.-M. Kaufman
S. Korte
B. H. Mitlak
D. Niese
R. Rizzoli
L. C. Rovati
J.-Y. Reginster
Publikationsdatum: 01.05.2010
Verlag: Springer-Verlag
Erschienen in: Osteoporosis International / Ausgabe 5/2010
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-010-1190-9

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

16.04.2024 | Spondylitis ankylosans | Nachrichten

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES)

Abstract

Summary

Introduction

Methods

Results

Conclusions

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

Zwei neue Alternativen zu TNF-Inhibitoren bei axSpA

Diclofenac-Gel versus Ibuprofen bei akuten Rückenschmerzen

Update Orthopädie und Unfallchirurgie

Springer Medizin

Abstract

Summary

Introduction

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2010

Transparency and trust

The US FRAX® filter: avoiding confusion or hindering progress?

A pilot case–control study on the alveolar bone density measurement in risk assessment for bisphosphonate-related osteonecrosis of the jaw

Risk factors for hip fracture in older adults: a case–control study in Taiwan

Estimation of serum osteocalcin and telopeptide-C in postmenopausal osteoporotic females

Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

Zwei neue Alternativen zu TNF-Inhibitoren bei axSpA

Diclofenac-Gel versus Ibuprofen bei akuten Rückenschmerzen

Update Orthopädie und Unfallchirurgie